NTRK Fusions in Colorectal Cancer: A Predictive Biomarker for Tumor-Agnostic TRK Inhibition

Introduction

Among the growing panel of predictive biomarkers in non, small cell lung cancer, NTRK gene fusions occupy a distinctive place. They are rare, they cross tumor-type boundaries, and they define eligibility for a class of drugs approved on a "tumor-agnostic" basis, meaning the biomarker, rather than the organ of origin, drives the therapeutic rationale. This article explains what an NTRK fusion is, how laboratories detect it, how each result is interpreted, and what a positive result informs about treatment eligibility. Throughout, the goal is educational; nothing here constitutes treatment advice for any individual patient.

What the Test Measures

The NTRK1, NTRK2, and NTRK3 genes encode the tropomyosin receptor kinases TRKA, TRKB, and TRKC, respectively, a family of receptor tyrosine kinases involved in normal neuronal signaling and development [2]. In cancer, a chromosomal rearrangement can fuse a portion of one of these NTRK genes to an unrelated partner gene. The resulting fusion product retains the TRK kinase domain but places it under abnormal control, producing a constitutively active, ligand-independent kinase that drives tumor proliferation and survival [2]. When such a fusion is present, it typically functions as an oncogenic driver, the dominant molecular engine of the tumor.

The predictive value follows directly from this biology: if the fusion kinase is what the tumor depends on, then a drug that blocks TRK kinase activity may disrupt the driver. Detecting the fusion is therefore not descriptive; it identifies a therapeutic vulnerability [2,6,7].

How It Is Tested

Testing is performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue, the standard specimen format in diagnostic pathology. Two complementary methods are commonly used in a tiered approach.

Pan-TRK immunohistochemistry (IHC) is a screening assay. A single antibody detects the shared TRK protein epitope, and aberrant expression can flag a possible fusion. IHC is fast, inexpensive, and widely available, making it a reasonable first pass. However, it is a screen, not a confirmatory test, staining patterns and sensitivity vary by which NTRK gene is involved and by fusion partner, so a positive or equivocal IHC result generally requires confirmation [4,5].

Next-generation sequencing (NGS) provides definitive characterization. RNA-based NGS is particularly valuable for fusion detection because it reads across the fusion junction and can identify the specific gene partners regardless of the intronic breakpoint, whereas DNA-based approaches may miss fusions with large or variable intronic regions. NGS confirms the presence of a genuine NTRK fusion and identifies the fusion partner, which is the molecularly meaningful event [5].

Scoring for this biomarker is fundamentally binary at the reporting level: a functional NTRK fusion is either present or absent. Unlike graded biomarkers with percentage thresholds, the clinically actionable question is whether a bona fide oncogenic fusion has been demonstrated.

Preanalytic factors matter. Adequate tumor cellularity, appropriate fixation, and sufficient preserved RNA quality all influence assay performance, especially for RNA-based NGS, which is sensitive to nucleic acid degradation in older or poorly preserved FFPE blocks.

What Each Result Means

"NTRK fusion present" indicates that a validated assay has detected an oncogenic NTRK1/2/3 rearrangement. In the tiered workflow, this typically means a positive screen confirmed by NGS, or direct NGS detection. This result identifies the tumor as fusion-driven and biomarker-eligible for the relevant therapy class (see below).

"Absent" indicates that no NTRK fusion was detected by the assay used. Interpretation should account for the method's limitations, a negative pan-TRK IHC screen, for instance, does not carry the same weight as complete NGS. Absence of a detectable fusion means the tumor does not qualify on this biomarker, though other actionable drivers may still be present and are usually assessed in parallel through broad molecular profiling [1,5].

What It Determines for Treatment Eligibility

A confirmed NTRK fusion informs eligibility for the TRK inhibitor class, small-molecule agents that target the aberrant TRK kinase. Larotrectinib and entrectinib are the archetypal agents developed specifically against NTRK fusion, positive malignancies [2,6,7]. Their approvals are notable for being tumor-agnostic: the fusion, not the anatomic site, defines the indicated population [2,8]. This means the same biomarker logic applies whether the fusion arises in lung, thyroid, salivary gland, or soft tissue.

It is important to frame this correctly: a positive result establishes that a patient's tumor belongs to the biomarker-defined group for which this drug class is relevant. It does not, by itself, dictate that any specific individual should receive any specific agent, that determination integrates clinical context, prior therapy, comorbidities, and shared decision-making with the treating oncologist. The pathology report supplies the molecular eligibility gate, not a prescription.

Caveats and What Is Evolving

Several nuances stand out. First, the screen-versus-confirm distinction is real: pan-TRK IHC can yield false positives and false negatives depending on the NTRK gene and fusion partner involved, so orthogonal confirmation by NGS is generally required before acting on a result. Second, because NTRK fusions are rare in lung cancer, roughly 0.23% of NSCLC (11/4,872 in one series), often arising without other canonical drivers, they are most efficiently captured within broad NGS panels that simultaneously interrogate the more common lung drivers, rather than as a standalone test [1,3]. Third, assay design affects detection, RNA-based methods are better positioned to capture the diversity of fusion partners than DNA-only approaches.

The field of predictive biomarkers is fast-moving, and the criteria that define "positive" for various markers remain under active refinement across oncology. In contrast to some contested, graded thresholds seen with other biomarkers, the NTRK fusion readout is comparatively clean, present or absent, but the reliability of that call still hinges on assay selection and confirmation strategy. The evidence supporting tumor-agnostic TRK inhibition rests on the fusion functioning as a true oncogenic driver [2,6,7], and rigorous confirmation ensures that the biomarker call reflects genuine biology.

---

References

1. Review. Lung Cancer: Targeted Therapy in 2025. Curr Oncol. 2025. PMC11941068 (verify).
2. Drilon A, et al. Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion. Journal of Hematology & Oncology. 2021. PMCID: PMC7863124.
3. Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018. PMID: 30215037. (NSCLC prevalence ~0.23%; vault S608.)
4. Hechtman JF, Benayed R, Hyman DM, et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol. 2017. PMID: 28719467. DOI: 10.1097/PAS.0000000000000911. (pan-TRK IHC screen; vault S119.)
5. Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases. Mod Pathol. 2020. PMID: 31375766. DOI: 10.1038/s41379-019-0324-7. (RNA- vs DNA-NGS; vault S120.)
6. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018. PMID: 29466156. DOI: 10.1056/NEJMoa1714448. (larotrectinib; vault S323.)
7. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours. Lancet Oncol. 2020. PMID: 31838007. DOI: 10.1016/S1470-2045(19)30691-6. (entrectinib; vault S421.)
8. Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (STARTRK/ALKA). Cancer Discov. 2017. PMID: 28183697. DOI: 10.1158/2159-8290.CD-16-1237. (tumor-agnostic, incl. NSCLC; vault S322.)